Ceftobiprole

• CAS: 209467-52-7
• Catalog Number: ACM209467527
• Category: Inhibitors
• Molecular Weight: 534.576
• Molecular Formula: C₂₀H₂₂N₈O₆S₂
• Description: Ceftobiprole (Ro 63-9141) is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci with a MIC90 value of 2 μg/mL for MRSA. Ceftobiprole also inhibits gram-positive and gram-negative pathogens.
• Synonyms: Ceftobiprole;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2Z)-2-(5-aMino-1,2,4-thiadiazol-3-yl)-2-(hydroxyiMino)acetyl]aMino]-8-oxo-3-[(E)-[(3R)-2-oxo[1,3-bipyrrolidin]-3-ylidene]Methyl]-,(6R,7R)-

Custom Q&A

What is the molecular formula of ceftobiprole?

The molecular formula of ceftobiprole is C20H22N8O6S2.

When was ceftobiprole created and modified?

Ceftobiprole was created on January 15, 2019, and modified on December 30, 2023.

What is the molecular weight of ceftobiprole?

The molecular weight of ceftobiprole is 534.6 g/mol.

What is the role of ceftobiprole?

Ceftobiprole is an antimicrobial agent and a cephalosporin antibiotic.

How does ceftobiprole work?

Ceftobiprole binds to and inactivates penicillin-binding proteins (PBPs) on the bacterial cell wall, interfering with cell wall strength and causing cell lysis.

What is the IUPAC name of ceftobiprole?

The IUPAC name of ceftobiprole is (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.

What is the InChIKey of ceftobiprole?

The InChIKey of ceftobiprole is VOAZJEPQLGBXGO-SDAWRPRTSA-N.

How is ceftobiprole classified in terms of cephalosporins?

Ceftobiprole is classified as a fifth-generation cephalosporin antibiotic.

Who discovered ceftobiprole and who is currently developing it?

Ceftobiprole was discovered by Basilea Pharmaceutica and is being developed by Johnson & Johnson Pharmaceutical Research and Development.

What infections is ceftobiprole specifically developed to treat?

Ceftobiprole is specifically developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).